Philip and Martin Low’s latest venture, Eradivir, was incorporated in February to develop a treatment that would fight the influenza virus, but COVID-19 prompted a tweak to the business plan.
For companies that pursue technological advances and innovative solutions, bias can have an enduring impact, making it easy for the cycle to be perpetuated.
Around the world, more than 80 vaccine projects are under development by pharmaceutical companies and university research laboratories.
The not-for-profit and its health research are a testament to the idea that all innovation is related—even when the connection appears tenuous at first glance.
The emerging health care field seeks to develop methods for replacing or reinvigorating damaged human organs, cells and tissues.
Health-data specialists at universities and research institutes in Indianapolis expect the virus to hit its peak between mid-April and early May, packing a punch that could cause about 800 new positive COVID-19 cases a day.
The Indianapolis-based drugmaker said it will combine its capability for quickly developing antibodies with AbCellera’s “rapid pandemic response platform,” with the goal of getting a treatment into clinics for human testing within four months.
Dr. Christopher Stobart and his students are focusing on an enzyme in the virus that could inhibit its replication, and plan to submit the findings to a virology journal in coming months.
Patient data is increasingly in the hands of for-profit industries. Insurance firms and other for-profit companies have been collecting patient data that yields important information that could be used to shape medical care and health policy.
Mucus may be gross, but we produce a lot of it. And new research is uncovering just how beneficial it is in the human body.
The spinoff, called Sexton Biotechnologies, has raised $5 million in outside investment and will spin off in October. The biotech develops cell and gene therapy tools used to grow cells for medical purposes.
After building and selling three companies and starting a fourth, Dr. Don Brown thought he had seen it all. Even so, he still gets an occasional surprise.
MindX founders think they’ve found a scientific way to measure pain and other hard-to-quantify mental health conditions, such as suicide risk, depression and post-traumatic stress disorder.
Should you avoid red meat? No. Should you strive for 10,000 steps a day? Not unless you just want to. So says Dr. Aaron Carroll, a pediatrician and researcher at the Indiana University School of Medicine who sees it as his life’s calling to debunk what he considers health myths and weak medical research.
Carroll uses Twitter, a New York Times column, blog post, podcast, videos and books to publish his findings on just about any health issue he thinks needs explaining or correcting.
In recent months, the drugmaker has won federal approval to sell a drug called Emgality for two conditions: migraine pain and cluster headaches.
The trials, which will begin in 2020, are part of a sweeping, five-year, $42 million federal research program known as Implementing Genomics in Practice. The first trial will examine whether early access to patients’ genomic data can help with treatment of high blood pressure, hypertension and chronic kidney disease.
Dr. Rainer Fischer is giving up the roles of CEO and chief scientific officer, but will continue as senior executive for innovation and discovery.
For a startup that has raised an eye-popping $71 million in just three years, Outpost Medicine LLC likes to keep a low profile. The young company, which is developing drugs for urinary and gastrointestinal disorders, is headquartered in small, unmarked space at the Parkwood Crossing office complex on East 96th Street. It has issued only a […]
Increasingly, top researchers are questioning whether drugs such as Lantus from Sanofi, Levemir and Novolog from Novo Nordisk A/S, and Humalog from Eli Lilly and Co. are really needed for many patients.
